Urinary Tract Infection Treatment Market by Disease Type and Geography - Forecast and Analysis 2021-2025

The urinary tract infection (UTI) treatment market share is expected to increase by USD 2.66 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.71%.

This urinary tract infection (UTI) treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers urinary tract infection (UTI) treatment market segmentation by type (uncomplicated UTI and complicated UTI) and geography (North America, Europe, Asia, and ROW). The urinary tract infection (UTI) treatment market report also offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd. among others.

What will the Urinary Tract Infection (UTI) Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Urinary Tract Infection (UTI) Treatment Market Size for the Forecast Period and Other Important Statistics

 

Urinary Tract Infection (UTI) Treatment Market: Key Drivers, Trends, and Challenges

The relation of UTI with several other factors leading to a rising incidence rate of UTI is notably driving the urinary tract infection (UTI) treatment market growth, although factors such as the development of antibacterial resistance may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the urinary tract infection (UTI) treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Urinary Tract Infection (UTI) Treatment Market Driver

One of the key factors driving growth in the urinary tract infection treatment market is the rising incidence rate of UTIs. Interconnection of UTIs with other healthcare conditions and changing lifestyle habits have led to the rising incidence of the disease. This, in turn, is expected to raise the demand for treatment facilities for UTIs. The disease is more common in women as compared with men. Around 50% of the women globally have a chance of developing UTIs at least once in their lifetime. This accounts for a large population and demands huge attention. Apart from gender, many other factors, such as obesity and diabetes, contribute to the rising incidence of UTIs.

Key Urinary Tract Infection (UTI) Treatment Market Trend

Rising R&D for effective treatment against superbugs/MDR microorganisms is a major trend influencing the urinary tract infection (UTI) treatment market growth. The development of MDR microorganisms is a huge challenge for the infectious disease industry, with hospital-acquired UTI being one of the major cases among them. Infections due to new species of microorganisms, which are also called superbugs, are resistant to most of the available treatments. These MDR microorganisms have a mortality rate of 25%-60%. This is a huge concern for healthcare providers across the globe. For instance, researchers at Queen's University Belfast, Ireland, have been studying the factors responsible for superbugs being resistant to the first line of treatment. This, in turn, has opened the opportunities to understand and develop a potential treatment to fight against killer infectious diseases. Countries all over the world are witnessing this problem, and therefore, a huge investment is expected in the development of their treatment. The EU, the Government of Canada, and a few developed countries have also taken various steps in developing innovative treatments against antimicrobial-resistant microorganisms.

Key Urinary Tract Infection (UTI) Treatment Market Challenge

The development of antibacterial resistance will be a major challenge for the urinary tract infection treatment market. UTI is primarily a bacterial infection. The development of antibacterial resistance organisms is a huge challenge for the global UTI treatment market. MDR microorganisms make UTIs more severe. MDR microorganisms are the species of organisms that exhibit resistance to several antimicrobial drugs. MDR bacteria are considered the most threatening group among all these organisms as they have shown a significant impact on public health. The MDR microorganisms, such as MDR E. coli, have been found to be a major infecting organism, especially in healthcare settings, and are a major point of concern for healthcare providers.

This urinary tract infection (UTI) treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global UTI treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the urinary tract infection (UTI) treatment market during the forecast period.

Who are the Major Urinary Tract Infection (UTI) Treatment Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Merck and Co. Inc.
• Pfizer Inc.
• SHIONOGI Co. Ltd.

 

This statistical study of the urinary tract infection (UTI) treatment market encompasses successful business strategies deployed by the key vendors. The urinary tract infection (UTI) treatment market is fragmented and the vendors are deploying organic and inorganic strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The urinary tract infection (UTI) treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Urinary Tract Infection (UTI) Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the urinary tract infection (UTI) treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of pharmaceuticals includes the following core components:

• Inputs
• Inbound logistics
• Operations
• Outbound logistics
• Marketing and sales
• Service
• Support activities
• Innovation

The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.

 

Which are the Key Regions for Urinary Tract Infection (UTI) Treatment Market?

For more insights on the market share of various regions Request for a FREE sample now!

35% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for urinary tract infection treatment in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The availability of a large number of companies has led to easy access to the treatment will facilitate the urinary tract infection (UTI) in treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the spread of COVID-19 across North America, especially in the US, reduced the demand for UTI treatment owing to the decrease in clinical presentations of patients to their general practitioners. As a result, the number of prescriptions for UTI treatment decreased in many North American countries such as the US, Canada, and Mexico and negatively impacted the market in focus in 2020. However, the market in the region is expected to recover gradually during the forecast period as COVID-19 vaccine distributions have helped resume visits to healthcare centers without the risk of contamination. Moreover, telehealth has helped in safe access to and delivery of healthcare services, which will help the market recover.

What are the Revenue-generating Type Segments in the Urinary Tract Infection (UTI) Treatment Market?

To gain further insights on the market contribUTIon of various segments Request for a FREE sample

The urinary tract infection (UTI) treatment market share growth in the uncomplicated UTI segment will be significant during the forecast period. The uncomplicated UTI treatment market holds the largest share of the global UTI treatment market. The uncomplicated UTI usually affects otherwise healthy individuals who have no neurological or structural urinary tract abnormalities. It can be subdivided into lower UTIs (cystitis) and upper UTIs (pyelonephritis). Cystitis is much more common than pyelonephritis. The estimated ratio between the two types of acute uncomplicated UTI is one case of pyelonephritis to 30 cases of cystitis. The reoccurrence of cystitis is a major problem being faced by women across the globe. About one-fourth of women globally suffer from cystitis and face the reoccurrence of the disease within six months of the infection. The reoccurrence rate of the disease increases with more than one prior case of UTI. The higher prevalence rate of uncomplicated UTIs as compared with complicated UTIs has led to the domination of the disease in the global UTI treatment market.

This report provides an accurate prediction of the contribUTIon of all the segments to the growth of the urinary tract infection (UTI) treatment market size and actionable market insights on post COVID-19 impact on each segment.

 

Urinary Tract Infection (UTI) Treatment Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 4.71%
Market growth 2021-2025	$ 2.66 million
Market structure	Fragmented
YoY growth (%)	3.97
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribUTIon	North America at 35%
Key consumer countries	US, Canada, Germany, China, and UK
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Urinary Tract Infection (UTI) Treatment Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive urinary tract infection (UTI) treatment market growth during the next five years
• Precise estimation of the urinary tract infection (UTI) treatment market size and its contribUTIon to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the urinary tract infection (UTI) treatment industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of urinary tract infection (UTI) treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch